Abstract
VP-14637 is the lead compound in a series of low molecular weight viral replication inhibitors which are under preclinical investigation by ViroPharma for the potential treatment of RSV infection [322651]. Phase I trials designed to evaluate the safety and pharmacokinetic prpfile of VR-14637 in healthy human volunteers have begun [385870]. VP-14637 is most active against pneumoviruses and the available data suggest that it is an inhibitor of RSV viral fusion activity [363716], [361097].
MeSH terms
-
Animals
-
Antiviral Agents / metabolism
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use*
-
Antiviral Agents / toxicity
-
Clinical Trials as Topic
-
Drugs, Investigational
-
Humans
-
Hydrazones
-
Phenols / metabolism
-
Phenols / pharmacology
-
Phenols / therapeutic use*
-
Phenols / toxicity
-
Respiratory Syncytial Virus Infections / drug therapy*
-
Respiratory Syncytial Virus Infections / virology
-
Respiratory Syncytial Virus, Human / drug effects
-
Structure-Activity Relationship
-
Tetrazoles / metabolism
-
Tetrazoles / pharmacology
-
Tetrazoles / therapeutic use*
-
Tetrazoles / toxicity
Substances
-
Antiviral Agents
-
Drugs, Investigational
-
Hydrazones
-
Phenols
-
Tetrazoles
-
VP-14637